pharmaphorum

JANUARY 26, 2022

It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.

Adverse Reactions 40

Adverse Reactions Chemotherapy Immunization Immunity 40

European Pharmaceutical Review

DECEMBER 27, 2023

Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.

Adverse Reactions 104

Adverse Reactions Immunization Immunity Medical Schools 104

Express Pharma

JUNE 18, 2024

This is the first Phase 3 trial to statistically evaluate an anti-PD-1 immunotherapy plus chemotherapy combination in patients with pMMR and dMMR tumours as two independent cohorts,” said Dr Ramez N. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of KEYTRUDA.

Chemotherapy 59

Chemotherapy Adverse Reactions Immunization Immunity 59

Pharmaceutical Technology

JANUARY 13, 2023

Enhertu has been approved to treat HER2-low breast cancer adult patients who have previously received at least one line of chemotherapy in the metastatic setting or who have seen disease recurrence during or within six months after the adjuvant chemotherapy. Enhertu’s safety profile was consistent with the previous clinical trials.

Adverse Reactions 128

Adverse Reactions Chemotherapy 128

Pharmaceutical Technology

FEBRUARY 5, 2023

The FDA approval is based on the data obtained from a global, multicentre, open-label Phase III TROPiCS-02 study conducted in 543 HR+/HER2- metastatic breast cancer patients who have received prior endocrine therapy, CDK4/6 inhibitor and two to four lines of chemotherapy for metastatic disease. Trodelvy showed 3.2

Adverse Reactions 105

Adverse Reactions Chemotherapy Labelling 105

Pharmaceutical Business Review

APRIL 30, 2024

During the trial, TIVDAK demonstrated a primary endpoint achievement of overall survival (OS) in patients with previously treated recurrent or metastatic cervical cancer, outperforming chemotherapy. The innovaTV 301 study showcased a 30% reduction in the risk of death when compared to chemotherapy, with a median OS of 11.5

Adverse Reactions 59

Adverse Reactions Chemotherapy 59

Pharmaceutical Technology

MARCH 23, 2023

Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. Diarrhoea, rash, pyrexia, nausea, musculoskeletal pain, fatigue and pruritus are the most common adverse reactions observed in patients treated with Zynyz. Partial response was seen in 22 patients and complete response in 12 patients.

Adverse Reactions 98

Adverse Reactions Compounding Chemotherapy Labelling 98

LifeProNow

APRIL 19, 2023

The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). director of the FDA’s Center for Biologics Evaluation and Research.

Adverse Reactions 130

Adverse Reactions Chemotherapy Labelling Immunization 130

Pharmaceutical Technology

NOVEMBER 23, 2022

Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.

Adverse Reactions 52

Adverse Reactions Chemotherapy Immunization Immunity 52

European Pharmaceutical Review

NOVEMBER 24, 2022

s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.

Chemotherapy 98

Chemotherapy Immunization Immunity Adverse Reactions 98

pharmaphorum

OCTOBER 19, 2020

The FDA’s approval covers use of Venclexta (venetoclax) in combination with azacytidine, or decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML in adults 75 years or older, or who have comorbidities preventing intensive induction chemotherapy. months compared with 4.1 months for those treated with LDAC alone.

Adverse Reactions 59

Adverse Reactions Chemotherapy Labelling 59

pharmaphorum

APRIL 1, 2021

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. The median progression free survival (PFS) for Sarclisa combination therapy was not reached at the time of the pre-planned interim analysis, the company said.

Adverse Reactions 59

Adverse Reactions Labelling Chemotherapy 59

LifeProNow

MAY 8, 2023

The standard therapy for these patients consists of intensive salvage immunochemotherapy followed by high-dose chemotherapy and HSCT for those whose disease responds to the salvage therapy and are eligible for transplant.

Chemotherapy 130

Chemotherapy Adverse Reactions 130

LifeProNow

APRIL 30, 2023

Adverse Reactions (ARs): In the data from the four randomized placebo-controlled trials, the most common ARs (≥ 10%) that occurred more frequently (≥ 2% over placebo) in XTANDI-treated patients were asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension.

Adverse Reactions 130

Adverse Reactions Chemotherapy Diabetes 130

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Who is Likely to Have an Adverse Reaction to Fluoride, and What are the Symptoms?

Adverse Reactions 116

Adverse Reactions Compounding Chemotherapy Labelling 116

The Thyroid Pharmacist

JULY 8, 2022

It’s important to note that selenium may also interact with other supplements and medications, such as cholesterol-lowering statin drugs, antacids, chemotherapy drugs, corticosteroids, niacin, and even birth control pills. At high enough levels, selenium can cause death (reports of this level of toxicity exist, but are extremely rare). (58,

Dosage 59

Dosage Immunization Immunity Diabetes 59

LifeProNow

APRIL 19, 2023

Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA. The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied.

Adverse Reactions 100

Adverse Reactions Vaccines Immunization Immunity 100

Express Pharma

DECEMBER 30, 2024

The most common adverse reactions (10 per cent) were fatigue, musculoskeletal pain, pruritus, rash, and cough. ORR was 24 per cent (95 per cent CI: 19,30) in the subcutaneous nivolumab and hyaluronidase-nvhy arm and 18 per cent (95 per cent CI: 14, 24) in the intravenous nivolumab arm.

Adverse Reactions 52

Adverse Reactions Dosage Chemotherapy Labelling 52

RX Note

FEBRUARY 23, 2023

G6PD Deficiency - Explaining G6PD Deficiency Ramadan - Medications during Ramadan fasting Adverse Drug Reactions Adverse Drug Reactions - All adverse reactions are adverse drug event Pharmacovigilance - To detect unreported ADRs Drug Allergy - Management vary based on the signs and symptoms Medicine-induced Discolouration - Red?

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58